AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 162 min read$CLOV

Toy Andrew sold $293K of CLOV

Toy Andrew (Chief Executive Officer) sold 62,711 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 ($0.29M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Toy Andrew
Published Jul 16, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 designation generally reduces the likelihood of a fundamental repricing.

02

Market read

A new, primary-source insider sale is disclosed, but it is pre-arranged under 10b5-1, so expected impact is limited.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction share count remains large, limiting inference from a single sale.

Relevance 3/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-16) discloses the 2026-07-15 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. /DE.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Toy Andrew sold 62,711 shares on 2026-07-15 at $4.6700, per a new SEC Form 4 filing.

Expected impact

Likely minimal price impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.

Key entities

  • issuer
    Clover Health Investments, Corp. /DE

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Toy Andrew

    CEO and officer/director who sold shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that typically limits interpretive value of insider sales.

Read at source← All news

Related articles

AUG 7
$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

yahoo.com6 min
AUG 6
$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

insurancebusinessmag.com9 min
AUG 5
$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

SEC EDGAR 8-K6 min
JUL 24
$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.

kavout.com4 min